American Society of Clinical Oncology (ASCO).Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.J Clin Oncol1996; 14: 2843–77.
2.
American Society of Clinical Oncology (ASCO).1997 update of recommendations for the use of tumor markers in breast and colorectal cancer.J Clin Oncol1998; 16: 793–5.
3.
American Society of Clinical Oncology (ASCO).1998 update of recommended breast cancer surveillance guidelines.J Clin Oncol1999; 17: 1080–2.
4.
HayesD.F., BastR.C., DeschC.E.Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.J Natl Cancer Inst1996; 88: 1456–66.
5.
AltmanD.G., De StavolaB.L., LoweS.B., StepniewskaK.A.A review of survival analysis published in cancer journals.Br J Cancer1995; 72: 515–8.
6.
AltmanD.G., LausenB., SauerbreiW., SchumakerM.Danger of using “optimal” cutpoints in the evaluation of prognostic factors.J Natl Cancer Inst1994; 86: 829–35.
7.
BiganzoliE., BoracchiP., DaidoneM.G., GionM., MarubiniE.Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers.Int J Biol Markers1999; 13: 107–23.
8.
AltmanD.G.Suboptimal analysis using ‘optimal’ cutpoints.Br J Cancer1998; 78: 556–7.
9.
Canadian Task Force on the Periodic Health Examination.The periodic health examination.Can Med Ass J1979; 121: 1193–254.
